Atlas FDA

RADIESSE INJECTABLE IMPLANT

FDA premarket approval P050052/S019 · decided 2009-07-13

Approval details

PMA number
P050052
Supplement
S019
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
RADIESSE INJECTABLE IMPLANT
Generic name
Implant, dermal, for aesthetic use
Applicant
Merz North America, Inc.
Date received
2009-01-14
Decision date
2009-07-13
Days to decision
180 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Franksville, WI
Statement
APPROVAL FOR MODIFICATIONS TO THE INSTRUCTIONS FOR USE TO PROVIDE DETAILED INSTRUCTIONS FOR MIXING RADIESSE WITH 2% LIDOCAINE HCL (RESULTING IN A FINAL CONCENTRATION OF 0.3% LIDOCAINE) PRIOR TO INJECTION FOR THE INDICATED USE OF SUBDERMAL IMPLANTATION FOR THE CORRECTION OF MODERATE TO SEVERE FACIAL WRINKLES AND FOLDS, SUCH AS NASOLABIAL FOLDS. THE MIXING OF RADIESSE AND LIDOCAINE IS TO BE ACCOMPLISHED USING A MIXING KIT THAT WILL BE MADE AVAILABLE SEPARATE FROM THE RADIESSE DEVICE.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
DESCRIBE PFD Patch (K172689)Merz North America, Inc.2017-11-29